Compounds of general formula I are used as labels in an electrochemical assay: (I) in which: Fc and Fc′ are substituted or unsubstituted ferrocenyl moieties, X is a C1 to C6 alkylene chain which is optionally interrupted by —O— or —NH—; Y is a C1 to C6 alkylene chain which is optionally interrupted by —O— or —NH—; Z is a C1 to C12 alkylene chain which may optionally be substituted and/or may optionally be interrupted by —O—, —S—, cycloalkyl, —CO—, —CONR1-, —NR1CO— or —NR1- in which R1 represents hydrogen or C1 to C4 alkyl; and R is a linker group. Compounds I are used to make labelled substrates, as well as functionalised compounds for making the labelled substrates.

The present invention is directed to novel compounds of Formula (I): pharmaceutically acceptable salts or solvates thereof, and their use, in particular in the treatment or prevention of malaria. ##STR00001##

The present invention is directed to novel compounds of Formula (I): pharmaceutically acceptable salts or solvates thereof, and their use, in particular in the treatment or prevention of malaria. ##STR00001##

The invention provides monoferrocenyl compounds of general formula I. The invention also provides substrates labelled with the compounds, functionalised derivatives of the compounds and methods of using the compounds, functionalised derivatives and labelled substrates in electrochemical assays.

The invention provides monoferrocenyl compounds of general formula I. The invention also provides substrates labelled with the compounds, functionalised derivatives of the compounds and methods of using the compounds, functionalised derivatives and labelled substrates in electrochemical assays.

The present invention relates to compounds of formula (I) (I) or pharmaceutically acceptable salts, and stereoisomers thereof, including enantiomers, racemic mixtures, mixtures of enantiomers, or combinations thereof, which are applicable for use in treating cancer diseases. The present invention further relates to a pharmaceutical composition comprising the above compounds.

##STR00001##

The present invention relates to compounds of formula (I) (I) or pharmaceutically acceptable salts, and stereoisomers thereof, including enantiomers, racemic mixtures, mixtures of enantiomers, or combinations thereof, which are applicable for use in treating cancer diseases. The present invention further relates to a pharmaceutical composition comprising the above compounds.

##STR00001##

There are provided a light absorption filter containing a resin, a dye having a main absorption wavelength band in a wavelength range of 400 to 700 nm, and a compound that generates a radical upon ultraviolet irradiation, where the resin is composed of a polymer having both a high affinity part and a low affinity part with respect to the dye and the compound that generates a radical upon ultraviolet irradiation, or a light absorption filter containing a dye having a main absorption wavelength band in a wavelength range of 400 to 700 nm and a resin composed of a polymer including a partial structure that generates a radical upon ultraviolet irradiation, an optical filter, a self-luminous display device, an organic electroluminescent display device, and a liquid crystal display device, in which this light absorption filter is used, as well as a manufacturing method for an optical filter.

There are provided a light absorption filter containing a resin, a dye having a main absorption wavelength band in a wavelength range of 400 to 700 nm, and a compound that generates a radical upon ultraviolet irradiation, where the resin is composed of a polymer having both a high affinity part and a low affinity part with respect to the dye and the compound that generates a radical upon ultraviolet irradiation, or a light absorption filter containing a dye having a main absorption wavelength band in a wavelength range of 400 to 700 nm and a resin composed of a polymer including a partial structure that generates a radical upon ultraviolet irradiation, an optical filter, a self-luminous display device, an organic electroluminescent display device, and a liquid crystal display device, in which this light absorption filter is used, as well as a manufacturing method for an optical filter.

Provided herein are a method of Ru(II)-catalyzed enantioselective synthesis of a cyclic compound and cyclic compounds formed therefrom. The method includes providing a precursor compound having an unfunctionalized C—H bond and activating the unfunctionalized C—H bond by reacting the precursor compound in the presence of co-catalysts including a Ru(II) arene complex and a chiral transient directing group (CTDG).